Analyst discuss the evolving landscape in Non-Small Cell Lung Cancer (NSCLC) (relevant companies SMMT TIL CBIO IMMP NVLT) on an Analyst/Industry conference call to be held on October 19.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Positive Outlook for Summit Therapeutics Driven by Anticipated HARMONi-6 Trial Success
- Promising Outlook for Summit Therapeutics: Buy Rating Driven by Anticipated HARMONi-6 Trial Performance and Share Price Growth
- Citi adds ’30-day upside catalyst watch’ on Summit Therapeutics
- Summit Therapeutics initiated with an Underweight at Barclays
- Summit Therapeutics’ Ivonescimab Shows Promising Trial Results, Offering a Risk-Mitigation Opportunity with a Buy Rating